Journal Article (Review Article)

DKFZ-2025-00538

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The Complexity of Malignant Glioma Treatment.

Kampers, L. F. C. ; Metselaar, D.DKFZ* ; Vinci, M. ; Scirocchi, F. ; Veldhuijzen van Zanten, S. ; Eyrich, M. ; Biassoni, V. ; Hulleman, E. ; Karremann, M. ; Stücker, W. ; Van Gool, S. W.

2025
MDPI Basel

This record in other databases:

Please use a persistent id in citations: doi:10.3390/cancers17050879

Abstract: Malignant glioma is a highly aggressive, therapeutically non-responsive, and deadly disease with a unique tumor microenvironment (TME). Of the 14 currently recognized and described cancer hallmarks, five are especially implicated in malignant glioma and targetable with repurposed drugs: cancer stem-like cells, in general, and glioma stem-like cells in particular (GSCs), vascularization and hypoxia, metabolic reprogramming, tumor-promoting inflammation and sustained proliferative signaling. Each hallmark drives malignant glioma development, both individually and through interactions with other hallmarks, in which the TME plays a critical role. To combat the aggressive malignant glioma spatio-temporal heterogeneity driven by TME interactions, and to overcome its therapeutic challenges, a combined treatment strategy including anticancer therapies, repurposed drugs and multimodal immunotherapy should be the aim for future treatment approaches.

Keyword(s): immunotherapy ; malignant glioma ; tumor microenvironment

---

Contributing Institute(s):

1. B062 Pädiatrische Neuroonkologie (B062)
2. DKTK HD zentral (HD01)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2025

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---